

GENERAL HOSPITAL

501 Mairis St. PO Box 1393 Charleston, WV 25325 (304) 388-5432

10/04/13 U.S. NRC Region I DNMS 2100 Renaissance Blvd. King of Prussia, PA 19406 Att: Janice Nguyen

Re: Mail Control #581369 Request for additional information regarding the addition of Lloyd J. Farinash, M.D. as an authorized user to NRC License #47-15473-01

Ms. Nguyen,

Per your request Dr. Farinash has received additional training in radiation safety and radiation protection for the safe handling and administration of beta and alpha emitting isotopes. As part of this training Dr. Farinash participated in the therapeutic administration of Ra-223 Xofigo as indicated below.

- Radiation safety and protection when handling beta and alpha emitting isotopes for therapeutic administration.
- Radiation safety concerns when handling volatile I-131 including the requirement for bioassay post administration or exposure.
- Requirements of a written directive.
- Overview of a quality management form which includes verification of the written directive, dual confirmation of the isotope and dose, patient confirmation and post dose assessment.
- Participation in the administration of 128 uCi of Ra-223 radium dichloride (Ra-223 Xofigo) on 10/2/2013 for the treatment of castration resistant prostate cancer.
- Also Included is a letter dated 9/19/2013 documenting additional radiation safety training performed by a medical physicist.

If there are any questions regarding this information please feel free to contact me at the telephone number provided below or you may e-mail your questions to me at steven.arza@cante.org.

Sincerely,

Steven Artz, M.D., RSO Charleston Area Medical Center Nuclear Medicine Department

501 Morris Street Charleston, WV 25325 (304) 388-7454 office

